Related Experiment Video

Updated: May 14, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Advances in antibiotic therapy for community-acquired pneumonia

Diego Viasus1, Carolina Garcia-Vidal, Jordi Carratalà

  • 1Department of Infectious Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain.

Current Opinion in Pulmonary Medicine
|February 21, 2013
PubMed
Abstract

Insights

Antibiotic resistance is increasing in community-acquired pneumonia (CAP) pathogens, necessitating new treatments. Newer antibiotics show promise for mild-to-moderate CAP, but data for severe cases are limited.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Public Health

Background:

  • Community-acquired pneumonia (CAP) is a significant global health concern.
  • Rising antibiotic resistance in CAP pathogens complicates treatment decisions.
  • Physicians face challenges in selecting effective antibiotic therapies for CAP.

Purpose of the Study:

  • To review current antibiotic treatment recommendations for CAP.
  • To provide updated information on antibiotic resistance patterns in CAP pathogens.
  • To discuss advancements in antibiotic therapy for CAP.

Main Methods:

  • Literature review of current guidelines and research on CAP antibiotic treatment.
  • Analysis of recent data on antibiotic resistance trends.
  • Evaluation of new antibiotic agents and clinical trial outcomes.

Main Results:

  • Increased resistance to common antibiotics (e.g., beta-lactams, macrolides) against CAP pathogens is reported.
  • Low fluoroquinolone resistance in Streptococcus pneumoniae persists.
  • Community-acquired methicillin-resistant Staphylococcus aureus and influenza A(H1N1)pdm09 are linked to severe CAP.
  • Newer antibiotics (cepholosporins, ketolides, quinolones) show in vitro activity against key CAP pathogens.
  • Randomized trials indicate newer antibiotics are as effective as conventional therapy for mild-to-moderate CAP.

Conclusions:

  • Antibiotic resistance in CAP has demonstrably increased over time.
  • Novel antibiotics for CAP treatment exhibit promising efficacy.
  • Further research is needed to establish the safety and effectiveness of new antibiotics in severe CAP cases.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.